Dyne Therapeutics’ (DYN) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report report published on Tuesday,Benzinga reports. They currently have a $50.00 target price on the stock.

Other analysts have also issued reports about the stock. Oppenheimer began coverage on shares of Dyne Therapeutics in a research note on Monday, June 2nd. They issued an “outperform” rating and a $34.00 price target for the company. JPMorgan Chase & Co. reduced their price target on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, March 21st. BMO Capital Markets began coverage on shares of Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 price target for the company. Raymond James Financial began coverage on shares of Dyne Therapeutics in a research note on Wednesday, June 11th. They issued an “outperform” rating and a $37.00 price target for the company. Finally, Evercore ISI started coverage on shares of Dyne Therapeutics in a research note on Thursday, May 29th. They issued an “outperform” rating and a $46.00 price target for the company. One analyst has rated the stock with a sell rating, one has given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.93.

Dyne Therapeutics Trading Down 0.7%

Shares of NASDAQ:DYN opened at $10.78 on Tuesday. The company has a 50 day moving average of $11.54 and a 200-day moving average of $14.71. The firm has a market cap of $1.23 billion, a P/E ratio of -3.00 and a beta of 1.16. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.17). Equities research analysts forecast that Dyne Therapeutics will post -3.44 EPS for the current year.

Institutional Trading of Dyne Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd raised its holdings in shares of Dyne Therapeutics by 378.6% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company’s stock worth $32,000 after purchasing an additional 2,446 shares in the last quarter. Quarry LP acquired a new stake in shares of Dyne Therapeutics during the first quarter valued at approximately $47,000. GF Fund Management CO. LTD. acquired a new stake in shares of Dyne Therapeutics during the fourth quarter valued at approximately $50,000. E Fund Management Co. Ltd. raised its holdings in shares of Dyne Therapeutics by 16.2% during the first quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company’s stock valued at $144,000 after acquiring an additional 1,923 shares during the period. Finally, Optimize Financial Inc acquired a new stake in shares of Dyne Therapeutics during the first quarter valued at approximately $154,000. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.